Six months into the COVID-19 pandemic, effective treatments have been frustratingly sparse. The RECOVERY clinical trial, however, revealed that treatment with dexamethasone, a classic synthetic glucocorticoid, enhanced survival of critically ill patients with COVID-19. In this Comment, we discuss the immunological impacts of glucocorticoid therapy for COVID-19. The corticosteroid dexamethasome has been shown to reduce mortality in patients hospitalized with COVID-19 who require mechanical ventilation. Here, the authors describe how this immunosuppressive drug might work.

中文翻译：

---

经过 62 年的免疫调节，地塞米松遇见了 COVID-19。

COVID-19 大流行已过去六个月，有效的治疗方法却十分稀少，令人沮丧。然而，RECOVERY 临床试验表明，使用地塞米松（一种经典的合成糖皮质激素）治疗可以提高 COVID-19 危重患者的生存率。在这篇评论中，我们讨论了糖皮质激素治疗对 COVID-19 的免疫学影响。皮质类固醇地塞米松已被证明可以降低需要机械通气的 COVID-19 住院患者的死亡率。在这里，作者描述了这种免疫抑制药物的作用原理。